<DOC>
	<DOCNO>NCT00838955</DOCNO>
	<brief_summary>This clinical trial patient Hodgkin Lymphoma respond standard treatment . The purpose study determine effect , good bad , Temsirolimus Hodgkin Lymphoma . The study also determine whether Temsirolimus tolerate patient Hodgkin Lymphoma previously treat chemotherapy .</brief_summary>
	<brief_title>Temsirolimus Relapsed/Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>Temsirolimus 25 mg IV infusion give weekly day 1 , 8 , 15 22 cycle . Patients assessed response CT scan second cycle , every cycle disease progression confirm . Patients treat Temsirolimus disease progression , six cycle . Continuation therapy beyond cycle discretion investigator .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Histologically confirm classical Hodgkin Lymphoma Lymphocyte Predominant Hodgkin Lymphoma progressive disease end previous therapy , define IWG criterion . Patient must nodular sclerosing , lymphocyte deplete , mixed cellularity Hodgkin Lymphoma ( Classical Hodgkin Lymphoma ) , Lymphocyte predominant Hodgkin Lymphoma . Baseline measurement evaluation must obtain within 4 week registration study . Abnormal PET scan constitute evaluable disease , unless verify CT scan appropriate imaging . A clearly define , bidimensionally measurable lymph node tumor mass measure least 2 cm diameter CT scan . Patient least one line prior chemotherapy . Patients relapse treatment radiation therapy alone eligible . Age &gt; equal 18 year . Both men woman member race ethnic group eligible trial . Women must pregnant breastfeed due lack information safety administration Temsirolimus pregnant lactating patient . All female childbearing potential must blood test urine study within 2 week prior registration rule pregnancy . Women childbearing potential sexually active male strongly advise use accept effective method pregnancy prevention . Patient must SWOG performance status 02 . Patient must prior treatment mTOR inhibitor . Patient must active infection time registration . Laboratory study obtain within two week study registration except noted otherwise . Allowable laboratory value list : Absolute neutrophil count &gt; equal 1,000/mm3 Hemoglobin &gt; equal 8 gm/dL Platelets &gt; equal 75,000/mm3 Serum creatinine &lt; equal two time upper limit normal . Creatinine measure within seven day registration . Total serum bilirubin &lt; equal â‰¤ 1.5 time upper limit normal . Total bilirubin measure within seven day registration . AST ( SGOT ) &lt; equal 3 time upper limit normal . ALT ( SGPT ) &lt; equal 3 time upper limit normal . Fasting total cholesterol &lt; equal 350 mg/dL . Fasting triglyceride level &lt; equal 400 mg/dL . Patient must life expectancy three month . Patient must receive prior allogeneic stem cell transplantation . Prior autologous stem cell transplantation six month prior registration acceptable . Patient must receive prior chemotherapy , biologic therapy radiation within three week prior registration , recover toxicity prior therapy ( Grade 0 1 ) . Patient must evidence active CNS disease . Patient must uncontrolled comorbid disease , include hyperlipidemia , hypertriglyceridemia , diabetes mellitus , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia Patient must psychiatric illness social situation would limit compliance study requirement . Patient must life expectancy three month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Hodgkin 's lymphoma</keyword>
	<keyword>relapse Hodgkin 's lymphoma</keyword>
	<keyword>refractory Hodgkin 's lymphoma</keyword>
	<keyword>Temsirolimus</keyword>
</DOC>